



RESIDENTS FORUM

[Translated article] RF – An Update on the Pharmacologic Management of Androgenetic Alopecia in Transgender Patients

FR – Actualización en el tratamiento farmacológico de alopecia androgenética en pacientes transgénero

O. Al-wattar-Ceballos*, L. Martínez-Montalvo, M. Montero-García

Servicio de Dermatología, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain

KEYWORDS

Alopecia;
Therapeutics;
Sexuality;
Dermatology

PALABRAS CLAVE

Alopecia;
Terapéutica;
Sexualidad;
Dermatología

The designation of a person as “transgender” or “trans” alludes to a mismatch between their gender identity and the sex assigned to them at birth.¹ “Cisgender” is the term used for individuals whose sex assigned at birth aligns with their gender identity.² The term “transmasculine” refers to a person whose gender identity is male and whose sex

assigned at birth is female. Conversely, when the gender identity is female and the sex assigned at birth is male, the term used is “transfeminine.”

A total of 9% of the population worldwide identifies as transgender. This percentage is lower in Spain (about 4% of the population).

These individuals often undergo gender-affirming hormonal therapies to develop sexually characteristic traits socially recognized as female or male.³

These therapies may complicate the treatment of various pathological conditions, including androgenetic alopecia, a condition where the male sex hormone dihydrotestosterone plays a prominent pathogenic role.⁴

Recently, an article has been published to guide therapy (Table 1) for androgenetic alopecia based on the safety and efficacy profile of different drugs relative to the type of patient: transmasculine or transfeminine.⁵

First-line pharmacological therapies for transgender individuals include 5% topical minoxidil once daily for transfeminine patients and up to twice daily for transmasculine patients, where hypertrichosis is a beneficial side effect. Oral finasteride at a dose of 1 mg per day is also included, as no clear variation in serum testosterone levels has been documented with its use, although its side effects must be discussed and agreed upon with the patient.

DOI of original article:

<https://doi.org/10.1016/j.ad.2023.12.008>

* Corresponding author.

E-mail address: oyalwattar@sescam.jccm.es

(O. Al-wattar-Ceballos).

<https://doi.org/10.1016/j.ad.2025.02.004>

0001-7310/© 2024 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article as: O. Al-wattar-Ceballos, L. Martínez-Montalvo and M. Montero-García, [Translated article] RF – An Update on the Pharmacologic Management of Androgenetic Alopecia in Transgender Patients, ACTAS Dermo-Sifiliográficas, <https://doi.org/10.1016/j.ad.2025.02.004>

Table 1 Pharmacological recommendations for the treatment of androgenetic alopecia in transgender patients.

	Transfeminine	Transmasculine
Topical minoxidil	Foam or 5% solution once daily	Foam or 5% solution twice daily
Oral minoxidil	1.25 mg once daily	2.5 mg once daily
Topical finasteride	0.25% solution once daily	0.25% solution once daily
Oral finasteride	1 mg once daily	1 mg once daily
Oral dutasteride	0.5 mg once daily	0.5 mg once daily
Oral spironolactone	Up to 200 mg once daily	Not recommended

Second-line therapies include oral minoxidil at doses of 1.25 mg or 2.5 mg for transfeminine and transmasculine patients, respectively, and 0.25% topical finasteride as monotherapy or combined with 2% minoxidil for transfeminine patients. Oral dutasteride at a dose of 0.5 mg daily is reserved for patients who have not responded to oral finasteride, while spironolactone is not recommended for transmasculine patients due to its potential to decrease serum testosterone levels and cause gynecomastia—this latter effect being desirable for transfeminine patients, where it is recommended at doses of up to 200 mg daily.⁵

Other therapeutic alternatives commonly used in cisgender populations, such as oral contraceptives with antiandrogenic progestogens, bicalutamide, dutasteride injections, or hair transplantation, have not been included.

Given the likely increase in hormonal therapies among transgender patients and their bodily impact on areas such as the scalp, it is essential for dermatologists to remain updated so they can understand which drugs to use to help their patients according to their social, cultural, and sexual realities.

Funding

None declared.

Conflicts of interest

None declared.

References

1. Ramos-Rodríguez D, Boix-Vilanova J, Sendagorta E. RF – Dermatology and the LGBTIQ+Community [FR – La Dermatología y el colectivo LGTBIQ]. *Actas Dermosifiliogr.* 2022;113:306–9, <http://dx.doi.org/10.1016/j.ad.2020.04.020>.
2. Safer JD, Tangpricha V. Care of transgender persons. *N Engl J Med.* 2019;381:2451–60, <http://dx.doi.org/10.1056/NEJMcp1903650>.
3. Mahfouda S, Moore JK, Siafarikas A, Hewitt T, Ganti U, Lin A, et al. Gender-affirming hormones and surgery in transgender children and adolescents. *Lancet Diabetes Endocrinol.* 2019;7:484–98, [http://dx.doi.org/10.1016/S2213-8587\(18\)30305-X](http://dx.doi.org/10.1016/S2213-8587(18)30305-X).
4. Dhurat R, Sharma A, Rudnicka L, Kroumpouzou G, Kassir M, Galadari H, et al. 5-Alpha reductase inhibitors in androgenetic alopecia: shifting paradigms, current concepts, comparative efficacy, and safety. *Dermatol Ther.* 2020;33:e13379, <http://dx.doi.org/10.1111/dth.13379>.
5. Gao JL, Streed CG Jr, Thompson J, Dommasch ED, Peebles JK. Androgenetic alopecia in transgender and gender diverse populations: a review of therapeutics. *J Am Acad Dermatol.* 2023;89:774–83, <http://dx.doi.org/10.1016/j.jaad.2021.08.067>.